At 7 years, the cumulative incidences of new vertebral fractures were significantly lower in the bazedoxifene (6.4%) and bazedoxifene 20 mg (7.6%) groups than in the placebo group (9.9%); the relative risk reductions were 36.5% and 30.4%, respectively (both p < 0.001). Bazedoxifene had no effect on the overall incidence of nonvertebral fractures.

Leave a Reply

Tu dirección de correo electrónico no será publicada. Los campos obligatorios están marcados con *

  • 3 × 4 =